The technology of tomorrow …

The fastest gateway to a successful launch is by choosing the right lead compound early. N2MO’s ex vivo models can provide guidance to you in your early drug discovery choices!

Contact us

Islandsbrygge 79C, 8502
DK-2300 København S

Phone: +45 3134 4896

About N2MO

New management

N2MO has appointed Preben Carøe as new CEO. Preben comes most recently from being Vice President and General Manager at Ametek. In a new position Björn Ursing, PhD, has been appointed COO. He comes most recently from working at Västerbotten Investment Agency in attracting foreign direct investments to northern Sweden.

By |December 7th, 2015|About N2MO|

N2MO Granted Award as Best Investment Opportunity 2015

The Business Angels Networks in Denmark held their annual meeting 2015 in Odense on the 21st. of May. In a very intense competition, N2MO was granted the winning position based on the level of interest in investing in the company. The meeting creates a unique platform for innovative start-up companies to meet with investors as […]

By |June 4th, 2015|About N2MO, Funding|

N2MO has been granted European (EPO) Patent

N2MO has been granted European (EPO) Patent for Screening Methods employing insects with Blood Brain Barrier
The patent covers insect models that are aimed to reflect vertebrate blood-brain barrier (BBB) penetration.

The value of the insect BBB model is that it can be just as predictive as expensive and time consuming animal models, and by using the […]

By |May 28th, 2009|About N2MO, Patents|